Goldman Sachs Lifts Price Target On Pfizer (PFE), Keeps Top Rating
Get Alerts PFE Hot Sheet
Price: $26.31 +0.19%
Rating Summary:
13 Buy, 20 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Rating Summary:
13 Buy, 20 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Join SI Premium – FREE
Earlier, Goldman Sachs raised its price target on Conviction Buy List-rated Pfizer (NYSE: PFE) from $23 to $25, citing room for upside.
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $21.57 yesterday.
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $21.57 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
- Goldman Sachs First Take on Tata Consumer Products (TGBL:IN) Earnings
- Novartis (NVS) PT Raised to $108 at CFRA
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Goldman Sachs Conviction Buy List, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!